Details for Patent: 8,119,648

Title:	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Abstract:	The present invention relates to substituted xanthines of general formula ##STR00001## wherein R.sup.1 to R.sup.3 are as defined herein, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).
Inventor(s):	Himmelsbach; Frank (Mittelbiberach, DE), Langkopf; Elke (Warthausen, DE), Eckhardt; Matthias (Biberach, DE), Mark; Michael (Biberach, DE), Maier; Roland (Biberach, DE), Lotz; Ralf (Schemmerhofen, DE)
Assignee:	Boehringer Ingelheim Pharma GmbH & Co. KG (Ingelheim am Rhein, DE)
Filing Date:	Jun 20, 2008
Application Number:	12/143,219
Claims:	1. A method of treating type II diabetes mellitus or obesity comprising administering to a patient in need thereof a pharmaceutically effective amount of a compound of the formula ##STR00006## wherein R.sup.1 denotes: a 4-methyl-2-quinazolinylmethyl group; R.sup.2 denotes a methyl group; and R.sup.3 denotes a 2-butyn-1-yl group; or an enantiomer, mixture thereof, or a salt thereof. 2. A method of treating type II diabetes mellitus or obesity comprising administering to a patient in need thereof a pharmaceutically effective amount of (13) 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-a- mino-piperidin-1-yl)-xanthine, or a salt thereof. 3. The method according to claim 1, wherein the compound of formula (I) is a physiologically acceptable salt formed with inorganic or organic acids or bases. 4. A method of treating type II diabetes mellitus or obesity, the method comprising administering to a patient in need thereof a pharmaceutical composition comprising a pharmaceutically acceptable amount of a compound according to claim 1 optionally together with one or more inert carriers and/or diluents. 5. A method of treating type II diabetes mellitus or obesity, comprising administering to a patient in need thereof a pharmaceutically effective amount of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-- 8-(3-(R)-amino-piperidin-1-yl)-xanthine, or a physiologically acceptable salt thereof with an inorganic or organic acid. 6. The method of claim 5, wherein said method treats type II diabetes mellitus. 7. A method of treating type II diabetes mellitus comprising administering to a patient in need thereof a pharmaceutically effective amount of 1-[(4-methyl-quinazolin-2-yl)methyl1]-3-methyl-7-(2-butyn-1-yl) -8-(3-(R)-amino-piperidin-1-yl)-xanthine. 8. A method of treating obesity comprising administering to a patient in need thereof a pharmaceutically effective amount of 1-[(4-methyl-quinazolin-2-yl)methyl]-3 -methyl-7-(2-butyn-1- yl)-8-(3-(R) -amino-piperidin-1-yl)-xanthine. 9. A method of treating type II diabetes mellitus, the method comprising administering to a patient in need thereof a pharmaceutical composition comprising a pharmaceutically acceptable amount of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R) -amino-piperidin-1-yl)-xanthine optionally together with one or more inert carriers and/or diluents. 10. A method of treating obesity, the method comprising administering to a patient in need thereof a pharmaceutical composition comprising a pharmaceutically acceptable amount of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-a- mino-piperidin-1-yl)-xanthine optionally together with one or more inert carriers and/or diluents.